Compare WETH & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WETH | GDTC |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | China | Singapore |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 15.5M |
| IPO Year | N/A | 2023 |
| Metric | WETH | GDTC |
|---|---|---|
| Price | $1.77 | $0.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 44.4K | ★ 1.7M |
| Earning Date | 11-12-2025 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.55 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $43,519,385.00 | $573,193.00 |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.74 | ★ N/A |
| Revenue Growth | 6.08 | ★ 63.03 |
| 52 Week Low | $0.76 | $0.73 |
| 52 Week High | $3.68 | $3.68 |
| Indicator | WETH | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 43.45 |
| Support Level | $1.44 | $0.87 |
| Resistance Level | $1.79 | $1.12 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 62.92 | 48.26 |
Wetouch Technology Inc is a touch panel supplier focused on R&D, production, and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for the automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots, and charging stations. The company sells touchscreen products both domestically in China and internationally. The company generates the majority of its revenue from the PRC, followed by the Republic of China and Korea.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.